Evaluation of Neuroprotective Effect of Minocycline

Phase 2

• Conditions: Retinal Detachment
• Interventions: Drug: placebo; Drug: Minocycline

• Registration Number: NCT01297816
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher.

In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-12
• Study Start: 2010-12
• Primary Completion: 2010-12
• Study First Submitted: 2011-01-19
• Study First Submitted QC: 2011-02-16
• Last Update Submitted: 2011-02-16
• Study First Posted: 2011-02-17
• Last Update Posted: 2011-02-17
• Study Completion: 2011-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• age over 8 years old
• gender of both sex
• normal liver and renal function
• informed consent received from all patients
• no pregnancy and no lactation
• minimal sun exposure

Exclusion Criteria

• old RD
• diabetic retina
• previous retinal surgery CRF& liver disfunction RD + PVR > B Hyper sensitivity to tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
placebo	placebo	100mg-
minocyclin	Minocycline	-

Primary Outcome Measures

Name	Time	Method
BCVA	changes of BCVA in 3 month	outcome method of measurement: Snellen chart

Secondary Outcome Measures

Name	Time	Method
finding of ERG changes	3 months	outcome method of measurement: ERG( testes)
finding of OCT changes	3 months	outcome method of measurement: OCT
finding of FAF changes	3 months	outcome method of measurement: FAF( testes)

Trial Locations

Locations (1)

Labbafinejad medical center; 🇮🇷 Tehran, Iran, Islamic Republic of